Evidence map›Paper›PMID 29163795›Full record

ArticleOncotarget2017

Oral 4-(

Caixia Wang, Yuanqiang Zheng, Michael A Sand Oval, Solange A Valdes, Zhe Chen, Dharmika S Lansakara-P, Maolin Du, Yanchun Shi, Zhengrong Cui

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Caixia Wang *Inner Mongolia Medical University, School of Basic Sciences, Inner Mongolia Key Laboratory of Molecular Biology, Hohhot, Inner Mongolia, China.
Yuanqiang Zheng *Inner Mongolia University, Research Center for Laboratory Animal Sciences, Hohhot, Inner Mongolia, China.
Michael A Sand Oval *The University of Texas at Austin, College of Pharmacy, Division of Molecular Pharmaceutics and Drug Delivery, Austin, Texas, USA.
Solange A ValdesThe University of Texas at Austin, College of Pharmacy, Division of Molecular Pharmaceutics and Drug Delivery, Austin, Texas, USA.
Zhe ChenInner Mongolia Medical University, School of Basic Sciences, Inner Mongolia Key Laboratory of Molecular Biology, Hohhot, Inner Mongolia, China.
Dharmika S Lansakara-PThe University of Texas at Austin, College of Pharmacy, Division of Molecular Pharmaceutics and Drug Delivery, Austin, Texas, USA.
Maolin DuInner Mongolia Medical University, School of Public Health, Hohhot, Inner Mongolia, China.
Yanchun ShiInner Mongolia Medical University, School of Basic Sciences, Inner Mongolia Key Laboratory of Molecular Biology, Hohhot, Inner Mongolia, China.
Zhengrong CuiInner Mongolia Medical University, School of Basic Sciences, Inner Mongolia Key Laboratory of Molecular Biology, Hohhot, Inner Mongolia, China.
Inner Mongolia Medical University · CNAustin College · USThe University of Texas at Austin · USInner Mongolia University · CN

Funding

Overcoming pancreatic tumor resistance to gemcitabineR01CA135274 · NCI · UNIVERSITY OF TEXAS AT AUSTIN · PI CUI, ZHENGRONG · 2008 to 2017
$2.8M
A Creative Integration of Omega-3 Fatty Acids into Pancreatic Cancer ChemotherapyR21CA179362 · NCI · UNIVERSITY OF TEXAS AT AUSTIN · PI CUI, ZHENGRONG · 2015 to 2016
$371k
NCI NIH HHS R01 CA135274NCI NIH HHS R21 CA179362
6 · The paper itself

Abstract

In spite of recent advances in targeted tumor therapy, systemic chemotherapy with cytotoxic agents remains a vital cancer treatment modality. Gemcitabine is a nucleoside analog commonly used in the treatment of various solid tumors, but an oral gemcitabine dosage form remain unavailable. Previously, we developed the 4-(

Indexed as

immunohistostainingoral bioavailabilityplasma pharmacokineticstumor growth inhibition

Identifiers

PMID29163795
PMCPMC5685716
OpenAlexW2760109017

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.